Compounded GLP-1s, explained: semaglutide, tirzepatide, and how 503B works
If you've shopped for GLP-1 weight-loss medications recently, you've seen wildly different prices for what looks like the same drug. A monthly Wegovy script can run $1,300+ at retail. A compounded semaglutide protocol from a US pharmacy can be a small fraction of that. The molecule is identical. So what's actually different?
The short answer
Compounded GLP-1s use the same active pharmaceutical ingredient (API) — semaglutide or tirzepatide — as brand drugs like Wegovy, Ozempic, Zepbound, and Mounjaro. The difference is who prepares the final injectable and under what regulatory pathway.
- Brand drugs are manufactured by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) and approved by the FDA for specific indications.
- Compounded drugs are prepared by a US pharmacy under a physician prescription, individualized for the patient.
Both can deliver the same active molecule. The price gap reflects branding, marketing, and the cost of clinical trials — not what's inside the vial.
What "503A" and "503B" actually mean
The Federal Food, Drug, and Cosmetic Act recognizes two categories of compounding pharmacy:
- 503A pharmacies compound patient-specific prescriptions on demand. They're regulated by state boards of pharmacy plus federal compounding rules.
- 503B outsourcing facilities operate under stricter standards similar to drug manufacturers (cGMP — Current Good Manufacturing Practice). They can prepare compounds in larger batches and ship to clinics or directly to patients.
Peptide12 only works with FDA-registered 503A and 503B pharmacies. We do not source from "research chemical" suppliers — full stop.
Why the price difference exists
Brand drug pricing reflects:
- The cost of clinical trials (Wegovy and Zepbound each ran multi-thousand-patient phase 3 programs).
- FDA review fees and post-market surveillance.
- Direct-to-consumer advertising and sales infrastructure.
- Manufacturer profit margin.
Compounded drugs strip out 1, 2, and 3. The API (semaglutide or tirzepatide) is sourced from FDA-registered API manufacturers, then prepared by the compounding pharmacy under prescription. You pay for the medication, the pharmacy's quality controls, and the clinical oversight — not the clinical trial machine.
What you should still expect
Compounded ≠ "less rigorous." The pharmacies Peptide12 works with run independent third-party assays for:
- Identity — confirming the molecule is what the label says
- Potency — confirming dose accuracy
- Sterility — confirming the injectable is microbe-free
- Endotoxin — confirming no bacterial endotoxin contamination
Certificates of analysis are available on request for any compounded medication.
Who shouldn't use compounded GLP-1s
Compounded GLP-1s are not appropriate for everyone. Your clinician will screen for:
- Personal or family history of medullary thyroid carcinoma or MEN2
- Active pancreatitis
- Severe gastroparesis
- Pregnancy or active attempts to conceive
- Type 1 diabetes
- Allergy to GLP-1 receptor agonists
If a compounded option isn't right, your clinician will say so — and may recommend a brand drug through your insurance or another protocol entirely.
The bottom line
Compounded GLP-1s exist because brand pricing has put effective obesity medication out of reach for most Americans. When prepared by FDA-registered 503A/503B pharmacies under physician prescription, they offer the same active ingredient at a fraction of the cost.
The thing to watch for is sourcing. If a vendor can't tell you which 503A or 503B pharmacy prepared the medication, or won't share a certificate of analysis, walk away.